{"id":"W3004630265","doi":"10.1016/j.ctrv.2020.101979","title":"Toxicity management with combination chemotherapy and programmed death 1/programmed death ligand 1 inhibitor therapy in advanced lung cancer","year":2020,"lang":"en","type":"review","venue":"Cancer Treatment Reviews","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Merck Sharp and Dohme","keywords":"Medicine; Nivolumab; Pembrolizumab; Atezolizumab; Lung cancer; Chemotherapy; Oncology; Internal medicine; Immunotherapy; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005605109,0.0005672849,0.00175891,0.0008257684,0.000118372,0.0006036457,0.0006613992,0.0005456231,0.002219304],"category_scores_gemma":[0.0006120069,0.000195689,0.0008406354,0.0008456607,0.0001626771,0.0005418998,0.0003937478,0.001256549,0.0005368413],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003988721,"about_ca_system_score_gemma":0.0005867439,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006232653,"about_ca_topic_score_gemma":0.001946398,"domain_scores_codex":[0.9998384,0.00004629816,0.00002745716,0.00002413365,0.00004856603,0.00001522885],"domain_scores_gemma":[0.9998124,0.0001016275,0.00004470026,0.000004040995,0.00002772224,0.000009414055],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0002195956,0.00007265365,0.0001473526,0.0180889,0.0002881963,0.0000676221,0.00001796929,0.000513838,0.0009414051,0.0007205204,0.01153165,0.9673903],"study_design_scores_gemma":[0.0008945543,0.001649195,0.004662978,0.02049048,0.002994296,0.002530693,0.00007181625,0.001117343,0.001577212,0.002673094,0.9612718,0.00006650093],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0002393568,0.9990321,0.0001157562,0.0001008374,0.00006852215,0.000008033095,0.00001557214,0.00000548031,0.0004143655],"genre_scores_gemma":[0.002662715,0.9960384,0.0003252633,0.0003251197,0.0001270974,0.00002013816,0.00005622375,0.000002136991,0.0004427649],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.002219304,"threshold_uncertainty_score":0.007424235,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05420534162604314,"score_gpt":0.3743132348462432,"score_spread":0.3201078932202001,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}